Heidelberg Pharma Valuation

Is HPHA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HPHA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate HPHA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate HPHA's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for HPHA?

Other financial metrics that can be useful for relative valuation.

HPHA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue7x
Enterprise Value/EBITDA-3.2x
PEG Ration/a

Price to Sales Ratio vs Peers

How does HPHA's PS Ratio compare to its peers?

The above table shows the PS ratio for HPHA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7x
2INV 2invest
7.9xn/a€61.5m
FYB Formycon
14.3x31.8%€872.3m
MDG1 Medigene
4.5x16.1%€33.4m
BIO3 Biotest
1.4x-4.1%€1.4b
HPHA Heidelberg Pharma
11.5x12.3%€109.5m

Price-To-Sales vs Peers: HPHA is expensive based on its Price-To-Sales Ratio (11.5x) compared to the peer average (7x).


Price to Earnings Ratio vs Industry

How does HPHA's PE Ratio compare vs other companies in the DE Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a35.4%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a35.4%
n/an/an/a
No more companies

Price-To-Sales vs Industry: HPHA is expensive based on its Price-To-Sales Ratio (11.5x) compared to the European Biotechs industry average (9x).


Price to Sales Ratio vs Fair Ratio

What is HPHA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HPHA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio11.5x
Fair PS Ratio2x

Price-To-Sales vs Fair Ratio: HPHA is expensive based on its Price-To-Sales Ratio (11.5x) compared to the estimated Fair Price-To-Sales Ratio (2x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst HPHA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€2.35
€10.05
+327.7%
12.4%€11.30€8.80n/a2
Sep ’25€2.51
€10.05
+300.4%
12.4%€11.30€8.80n/a2
Oct ’24€3.42
€9.17
+168.0%
23.8%€12.00€6.70n/a3
Sep ’24€3.46
€9.17
+164.9%
23.8%€12.00€6.70€2.513
Aug ’24€3.55
€9.17
+158.2%
23.8%€12.00€6.70€2.673
Jul ’24€3.72
€8.87
+138.4%
28.6%€12.00€5.80€2.603
Jun ’24€3.81
€8.87
+132.7%
28.6%€12.00€5.80€2.893
May ’24€4.00
€8.87
+121.7%
28.6%€12.00€5.80€3.013
Apr ’24€4.42
€10.30
+133.0%
12.8%€12.00€8.80€3.123
Mar ’24€4.86
€10.30
+111.9%
12.8%€12.00€8.80€3.063
Feb ’24€5.04
€10.97
+117.6%
20.1%€14.00€8.80€3.183
Jan ’24€4.93
€10.97
+122.4%
20.1%€14.00€8.80€3.743
Dec ’23€5.84
€10.97
+87.8%
20.1%€14.00€8.80€2.753
Nov ’23€5.04
€10.97
+117.6%
20.1%€14.00€8.80€2.753
Oct ’23€4.50
€10.57
+134.8%
23.0%€14.00€8.80€3.423
Sep ’23€5.54
€11.13
+101.0%
19.9%€14.00€8.60€3.463

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies